Belite Bio Completes Enrollment in DRAGON II Trial for Stargardt Disease Treatment
Event summary
- Belite Bio has completed enrollment of 60 adolescent subjects in the Phase 2/3 DRAGON II clinical trial for tinlarebant, a treatment for Stargardt disease type 1 (STGD1).
- The trial is being conducted across Japan, the United States, and the United Kingdom.
- Belite Bio plans to file a New Drug Application (NDA) with the FDA in the first half of 2026.
- Tinlarebant has previously demonstrated a 36% reduction in lesion growth in the pivotal Phase 3 DRAGON trial.
The big picture
Belite Bio's completion of the DRAGON II trial enrollment marks a critical step in the development of tinlarebant, a novel oral therapy for Stargardt disease. The strategic significance lies in the potential to address a rare and debilitating condition with no current approved treatments. The company's ability to align the trial with regulatory requirements in both the U.S. and Japan positions it for potential dual approvals, expanding market opportunities. The broader context includes the growing focus on orphan drugs and the need for innovative therapies in degenerative retinal diseases.
What we're watching
- Regulatory Approval
- Whether the FDA will approve tinlarebant based on the DRAGON II trial data and the planned NDA submission in 1H 2026.
- Clinical Efficacy
- How the results of the DRAGON II trial will compare to the previously demonstrated 36% reduction in lesion growth.
- Market Potential
- The pace at which Belite Bio can commercialize tinlarebant if approved, given the significant unmet medical need in STGD1.